Zealand Pharma A/S (ZEAL.CO)

DKK 443.1

(7.97%)

Market Cap (In DKK)

31.31 Billion

Revenue (In DKK)

342.78 Million

Net Income (In DKK)

-703.73 Million

Avg. Volume

320.8 Thousand

Currency
DKK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
342.2-972.0
PE
-27.28
EPS
-16.24
Beta Value
0.541
ISIN
DK0060257814
CUSIP
-
CIK
-
Shares
70677799.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Adam Sinding Steensberg M.D.
Employee Count
-
Website
https://www.zealandpharma.com
Ipo Date
2010-11-23
Details
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

More Stocks